. 2021 Mar 17;35(11):3314–3318. doi: 10.1038/s41375-021-01210-8

Table 1.

Demographic features, prior therapies and response to dabrafenib of the 10 HCL patients.

Pt.	Sex	Age	Previous therapies	Blood counts and spleen size:				Response to dabrafenib	Weeks of treatment until best response	Total weeks of treatment	Progression-free survival (in months^b)	Treatment-free survival (in months^c)
Pt.	Sex	Age	Previous therapies	Neut /mm³	PLT ×10³/mm³	Hb g/dL	Spleen^a cm	Response to dabrafenib	Weeks of treatment until best response	Total weeks of treatment	Progression-free survival (in months^b)	Treatment-free survival (in months^c)
1	M	55	IFN, CDA, CDA, IFN, RTX, RTX, IFN, DCF+RTX, Splenectomy	71	13	7.5	–	PR	8	12	42	56
2	M	52	IFN, CDA, CDA	959	55	13.8	16	PR	4	12	5.5	10
3	M	52	DCF, CDA	701	65	12.1	23.5	PR	12	12	7	13
4	M	63	CDA, CDA	231	56	14.2	11	PR	8	12	10	12
5	M	55	IFN, CDA, CDA, CDA	630	103	12.2	14.5	CR	12	12	15.5	31
6	M	79	Splenectomy, IFN, CDA, CDA, IFN, CDA, RTX, RTX, VEM, VEM	290	36	9.5	–	PR	8	12	7	9
7	M	75	CDA^d	789	81	10.6	11	CR	8	8	60.5+	59+
8	M	61	CDA, RTX, IFN, DCF	80	11	8.6	28	MR	8	12	3.5+	0.27
9	M	81	DCF, DCF, CDA, VEM, VEM	500	95	10.8	13	CR	12	12	14	21
10	M	75	IFN	410	31	11.4	20	MR	4	12	7	14.5

Neut. neutrophils, PLT platelets, Hb hemoglobin, IFN interferon, CDA cladribine, DCF pentostatin (deoxycoformycin), RTX rituximab, VEM vemurafenib, PR partial response, CR complete response, MR minor response.

^aLongest diameter.

^bFrom the start of treatment.

^cFrom the end of treatment.

^dPrimary refractory.